Skylands Capital LLC Grows Stock Holdings in Haemonetics Co. (NYSE:HAE)

Skylands Capital LLC grew its holdings in Haemonetics Co. (NYSE:HAE) by 16.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,175 shares of the medical instruments supplier’s stock after acquiring an additional 3,875 shares during the period. Skylands Capital LLC owned about 0.05% of Haemonetics worth $2,122,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its position in Haemonetics by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 5,880 shares of the medical instruments supplier’s stock worth $472,000 after acquiring an additional 400 shares during the period. Nisa Investment Advisors LLC raised its position in Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 632 shares during the period. F M Investments LLC acquired a new position in Haemonetics during the third quarter worth $8,237,000. Harbor Capital Advisors Inc. raised its position in Haemonetics by 117.9% during the third quarter. Harbor Capital Advisors Inc. now owns 56,164 shares of the medical instruments supplier’s stock worth $4,514,000 after acquiring an additional 30,389 shares during the period. Finally, Verdence Capital Advisors LLC acquired a new position in Haemonetics during the third quarter worth $302,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Trading Down 0.7 %

Shares of HAE stock opened at $62.98 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a market cap of $3.16 billion, a PE ratio of 24.79, a price-to-earnings-growth ratio of 1.11 and a beta of 0.39. The company has a 50-day moving average of $72.24 and a two-hundred day moving average of $76.37. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the subject of a number of research analyst reports. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Needham & Company LLC reduced their target price on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. JMP Securities cut their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Finally, Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.